Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Net Cash Flow: 2016-2025

Historic Net Cash Flow for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to -$2.6 million.

  • UroGen Pharma's Net Cash Flow rose 97.26% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.6 million, marking a year-over-year decrease of 689.79%. This contributed to the annual value of $77.2 million for FY2024, which is 95.04% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Net Cash Flow is -$2.6 million, which was up 76.63% from -$11.1 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Net Cash Flow ranged from a high of $99.2 million in Q3 2023 and a low of -$94.8 million during Q3 2024.
  • Its 3-year average for Net Cash Flow is $3.2 million, with a median of -$11.1 million in 2025.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 551.35% in 2022, then surged by 639.49% in 2024.
  • Over the past 5 years, UroGen Pharma's Net Cash Flow (Quarterly) stood at -$11.0 million in 2021, then surged by 343.45% to $26.7 million in 2022, then slumped by 190.93% to -$24.3 million in 2023, then skyrocketed by 293.72% to $47.1 million in 2024, then surged by 97.26% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$11.1 million for Q2 2025, and -$68.0 million during Q1 2025.